Rheumatoid arthritis drug tied to fewer deaths in COVID patients

Two new studies have revealed that the rheumatoid arthritis drug tocilizumab is associated with lower death rates in COVID-19 patients receiving mechanical ventilation. Tocilizumab blocks interleukin-6 (IL-6), an inflammatory protein involved in a potential "cytokine storm" that can lead to respiratory failure in coronavirus patients.

In the first single-center observational study, published late last week in Clinical Infectious Diseases, University of Michigan at Ann Arbor researchers found that tocilizumab was linked to a 45% reduction in risk of death (hazard ratio [HR], 0.55 (95% confidence interval [CI], 0.33 to 0.90) and improved status after adjusting for propensity score inverse probability weighting (IPTW).

In the second study, researchers in Milan found that tocilizumab halved the death rate of coronavirus patients compared with standard care but lengthened hospital stays, according to a study last week in the Journal of Infection.

Improvement despite more superinfections

The Michigan study involved 78 COVID-19 patients hospitalized at Michigan Medicine on mechanical ventilation who received tocilizumab and 76 who did not from Mar 9 to Apr 20.

Tocilizumab was tied to twice the frequency of superinfections (54% vs 26%; P < 0.001), most attributed to a large increase in ventilator-associated pneumonia (45% vs 20%; P < 0.001); superinfections are secondary infections with a different pathogen resistant to the treatment given to treat first infections. Roughly half of cases of bacterial pneumonia were identified as due to Staphylococcus aureus.

But there was no difference in 28-day death rate between patients given tocilizumab with or without a superinfection (8 of 37 [22%] vs 6/41 [15%]; P = 0.42). In addition to the 45% lower death rate overall, case-fatality rate at 28 days in tocilizumab-treated patients was halved (18% vs 36%).

Tocilizumab-treated patients had greater improvement on a six-point ordinal scale that assessed mechanical ventilation, development of superinfections, and hospital release (odds ratio [OR], ~0.6; P 0.03) in IPTW-weighted models.

The status improvement in the tocilizumab-treated group is related to the statistically significant increase in patients released from the hospital during the study period (56% vs 40%; P = 0.04). Seventeen patients in each group were still hospitalized at the end of follow-up, but only 3 of 17 (18%) of tocilizumab-treated patients were still receiving mechanical ventilation, versus 8 of 17 (47%) of controls.

Although the two groups were similar, patients who received tocilizumab were younger (mean age, 55 vs 60), were less likely to have chronic lung disease (10% vs 28%) or chronic kidney disease (35% vs 49%), and had lower D-dimer levels (indicating blood clots) at intubation than control patients. Median follow-up was 47 days (range, 28 to 67).

Most patients in both groups were intubated either within 48 hours of transfer to the facility or within 24 hours of admission.

"These data are encouraging and can help to inform clinical practice while results from randomized controlled trials of IL-6 inhibitors are awaited," the authors wrote.

Critically ill patients and clinical benefit

The Italian single-center retrospective study compared the outcomes of 74 COVID-19 patients treated with tocilizumab starting Mar 13 to Apr 3 with those of 148 matched controls. While patients with less severe COVID-19 did not seem to benefit from tocilizumab, those with critical illness did derive a benefit.

Patients treated with tocilizumab had improved survival (HR, 0.49; 95% CI, 0.26 to 0.95; P = 0.035) compared with controls but also had longer hospital stays (HR, 1.66; 95% CI, 1.08 to 2.52; P = 0.019), primarily driven by biochemical, respiratory, and infectious adverse events.

At the end of follow-up, 35% of the 74 tocilizumab-treated patients had clinical deterioration in terms of mechanical ventilation requirements or death, while 65% were stable or improved.

Tocilizumab-treated patients had increased IL-6 levels 12 hours after drug administration, but later, IL-6 levels in those continuing to show deterioration kept increasing, while others had lesser increases.

Over the 7 days after tocilizumab treatment, C-reactive protein levels (indicating inflammation) decreased substantially, and levels of leukocyte and lymphocyte white blood cells, and platelets (involved in clotting) increased.

D-dimer levels increased dramatically by day 5 then decreased without returning to baseline. Moreover, a substantial increase in alanine transaminase levels (indicating liver inflammation or damage) was seen at day 7.

Patients who underwent noninvasive mechanical ventilation after hospitalization benefited from tocilizumab, but those who received the drug outside of the intensive care unit (ICU) needed emergent noninvasive mechanical ventilation after receiving tocilizumab.

Twenty-seven infectious adverse events occurred in 24 patients (32%), 21 of them in ICU patients. Eleven serious events (15%) occurred, six of them due to sepsis caused by gram-negative bacteria, two due to sepsis caused by gram-positive bacteria, one due to candidemia, one due to a lung abscess, and one caused by an epidural abscess. Of all patients with adverse events, one died from septic shock after release from the ICU.

The number of tocilizumab doses didn't seem to affect survival (HR, 0.75; 95% CI, 0.20 to 2.79; P = 0.38). Nor did baseline IL-6 levels (HR, 0.45; 95% CI, 0.10 to 2.39; P = 0.376).

Median patient age was 59 years; 82% were men, 82% were white, and 70% were critically ill.

"This study confirms the potentially effectiveness of [tocilizumab] on COVID-19—especially in critically ill patients—with a reliable comparison group that allows to weigh the potential clinical impact of this treatment," the authors wrote. "Nevertheless, we suggest using it cautiously due to drug-related adverse events, remarkably transitory respiratory worsening, and bacterial infections." 

According to the authors, several trials of tocilizumab in coronavirus patients with different study designs, drug combinations, and target populations are listed on ClinicalTrials.gov and should yield more details of the use of tocilizumab in these patients.

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Unorthodox Philanthropy logo and text 'Leading Underwriter'3M logoGilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»